Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1056P - Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study

Date

16 Sep 2021

Session

ePoster Display

Presenters

Ivan Marquez-Rodas

Citation

Annals of Oncology (2021) 32 (suppl_5): S867-S905. 10.1016/annonc/annonc706

Authors

I. Marquez-Rodas1, M.A. Berciano Guerrero2, E. Muñoz Couselo3, J.L. Manzano4, G. Crespo Herrero5, A. Soria6, P. Cerezuela7, T. Puertolas Hernandez8, A. Berrocal9, M. Majem Tarruella10, L. Bellido Hernández11, E. Espinosa12, A. Garcia Castano13, J. Medina Martínez14, L.A. Fernandez Morales15, C. Aguado de la Rosa16, L. Gutierrez Sanz17, R. Lopez Castro18, P. Ayala de Miguel19, S. Martin Algarra20

Author affiliations

  • 1 Medical Oncology, Hospital General Universitario Gregorio Marañon, 28009 - Madrid/ES
  • 2 Oncology Department, Unidad Intercentros de Oncología. HURyVV (Hospitales Universitarios Regional y Virgen de la Victoria de Málaga) . IBIMA (Instituto de Investigación Biomédica de Málaga), 29010 - Malaga/ES
  • 3 Medical Oncology, Vall d'Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 4 Medical Oncology, ICO-Badalona, H. Germans Trias i Pujol, Barcelona/ES
  • 5 Medical Oncology, Hospital Universitario de Burgos, Burgos/ES
  • 6 Medical Oncology, Hospital Universitario Ramón y Cajal, 28034 - Madrid/ES
  • 7 Medical Oncology, Hospital Virgen de la Arrixaca, Murcia/ES
  • 8 Medical Oncology Dept., Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 9 Medical Oncology, Hospital General Universitario Valencia, 46014 - Valencia/ES
  • 10 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 - Barcelona/ES
  • 11 Medical Oncology, Complejo Asistencial Universitario de Salamanca, 37007 - Salamanca/ES
  • 12 Medical Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 13 Medical Oncology, Hospital Universitario Marqués de Valdecilla, 39008 - Santander/ES
  • 14 Medical Oncology, Hospital Virgen de la Salud, 45004 - Toledo/ES
  • 15 Medical Oncology, Parc Taulí University Hospital, Sabadell/ES
  • 16 Medical Oncology, Hospital Clinico San Carlos, Madrid/ES
  • 17 Medical Oncology, Hospital Universitario Puerta de Hierro, Madrid/ES
  • 18 Medical Oncology, Hospital Clínico Universitario de Valladolid, Valladolid/ES
  • 19 Medical Oncology, University Hospital San Pedro de Alcántara, Caceres/ES
  • 20 Oncology Department, Clinica Universidad de Navarra, 31008 - Pamplona/ES
More

Abstract 1056P

Background

Targeted therapy (TT) and immune-check-point inhibitors (CPi) have improved the survival of patients (pts) with advanced melanoma (mel). Real-world data of these treatments are needed to confirm the results of clinical trials.

Methods

GEM1801 is a prospective observational study including 400 pts with resected stage III and advanced mel diagnosed since 2018 in Spain. Objectives were to analyze the clinical and pathological presentation, treatment choice and health outcomes. We report results of the advanced mel group (N=357).

Results

Median age was 65 years, ECOG 0-1 85.7% and AJCC 8th Ed stage IV 90.7% (24.9% a, 14.3% b, 34.7% c and 16.9% d). BRAF, reported in 348 pts (97.5%), was BRAF V600-mutated (Mut) in 50.4%. LDH, reported in 302 pts (84.6%), was > upper limit normal (ULN) in 32.8%. First-line (1L) was CPi in 94.9% of BRAF-wild-type (wt) and 30% of BRAF V600-Mut. For TT, BRAF+MEK inhibitors were selected as 1L in 64.1% of BRAF V600-Mut. Median follow up was 18.3 months (m) (95% CI 17.1-19.6). Median overall survival (OS) was (estimated) 28.1 m (95% CI 22.9-NA). With 1L CPi, 12 and 18-m OS was 79.4% and 70.5% respectively for BRAF-wt group and 90.2% and 82% for BRAF V600-Mut (median OS not reached in either group). In pts with BRAF V600-Mut and TT, 12 and 18m OS was 62.4% and 50.9% respectively and median OS 18.5m (95% CI 13.3-28.1). OS according to ECOG, LDH and M1 stage is in the table G3-4 AEs appeared in 7.9% of pts treated with TT and 9.2% with CPi. Table: 1056P

Factor % % 12 - 18 m OS *p (Cox/log-rank) <0.05
BRAF V600 Mut TT ECOG 0-1 vs >1 77/33 67.5 - 56.4* vs 44 - 35
LDH ≤ULN vs >ULN 53/47 78 – 63* vs 46.7 - 39.8
M1 a-b vs c-d 59/41 75.6 – 71* vs 53.1 - 37
BRAF V600 Mut CPi ECOG 0-1 vs >1 98/2 90.2 - 85.2 vs NA
LDH ≤ULN vs >ULN 72/28 88.5 - 88.5 vs 90 - 80
M1 a-b vs c-d 55/45 84.2 - 84.2 vs 91.3 - 82.6
BRAF wt CPi ECOG 0-1 vs >1 89/11 83.9 - 74.9* vs 46.2 - 30.8
LDH ≤ULN vs >ULN 66/34 89 – 82* vs 61.1 - 43.3
M1 a-b vs c-d 56/44 90.1 - 79.5* vs 67.3 - 59

Conclusions

Survival of pts with advanced mel is similar to reported in clinical trials. 1L TT was chosen for 2/3 BRAF V600-Mut cases while 1/3 were treated with CPi. OS in pts treated with CPi seems superior to TT in BRAF V600-Mut group although potential bias must be considered since stage, LDH and ECOG impacted OS.

Clinical trial identification

NCT03605771.

Editorial acknowledgement

Legal entity responsible for the study

Spanish Melanoma Group.

Funding

Novartis, Pierre Fabre, Incyte, BMS, MSD and Roche.

Disclosure

I. Marquez-Rodas: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Regeneron; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Highligth Therapeutics; Financial Interests, Personal, Advisory Board: Bioline Rx; Financial Interests, Personal and Institutional, Invited Speaker, GEM1802 clinical trial: Pierre Fabre; Financial Interests, Institutional, Invited Speaker, GEM1801 clinical study: Novartis; Financial Interests, Institutional, Invited Speaker, GEM1801 clinical study: BMS; Financial Interests, Institutional, Invited Speaker, GEM1801 clinical study: Roche; Financial Interests, Institutional, Invited Speaker, GEM1801 clinical study: Pierre Fabre; Financial Interests, Institutional, Invited Speaker, GEM1801 clinical study: Incyte; Financial Interests, Institutional, Invited Speaker, GEM1801 clinical study: MSD; Financial Interests, Institutional, Invited Speaker, National coordinator of Spotlight 203 clinical trial: Highlight Therapeutics; Non-Financial Interests, Invited Speaker: Spanish Melanoma Group. M.A. Berciano Guerrero: Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Invited Speaker: Pharmamar; Financial Interests, Personal, Advisory Role: Pharmamar; Financial Interests, Personal, Invited Speaker: Kyowa Kirin. E. Muñoz Couselo: Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Other, travel and accommodation: BMS; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Invited Speaker, travel and accommodation: MSD; Financial Interests, Personal, Speaker’s Bureau: Pierre Fabre. G. Crespo Herrero: Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: EUSA pharma; Financial Interests, Personal, Speaker’s Bureau: Merck; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Speaker’s Bureau: EUSA pharma; Financial Interests, Personal, Speaker’s Bureau: Eisai; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, , Invited Speaker, travel and accommodation: Roche. A. Soria: Financial Interests, Personal, Other, honoraria: Roche; Financial Interests, Personal, Other, honoraria: Merck Serono; Financial Interests, Personal, Other, honoraria: Novartis; Financial Interests, Personal, Other, honoraria: BMS; Financial Interests, Personal, Other, honoraria: Sanofi; Financial Interests, Personal, Other, honoraria: Pierre Fabre; Financial Interests, Personal, Other, honoraria: MSD; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Merck Serono; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Speaker’s Bureau: Merck; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal, Speaker’s Bureau: Pierre Fabre; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Expert Testimony: Roche; Financial Interests, Personal, Expert Testimony: Merck; Financial Interests, Personal, Expert Testimony: Novartis; Financial Interests, Personal, Expert Testimony: BMS; Financial Interests, Personal, Expert Testimony: Sanofi; Financial Interests, Personal, Expert Testimony: Pierre Fabre; Financial Interests, Personal, Expert Testimony: Merck; Financial Interests, Personal, Other, travel accommodation: Novartis; Financial Interests, Personal, Other, travel accommodation: BMS; Financial Interests, Personal, Other, travel accommodation: MSD. P. Cerezuela: Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Speaker’s Bureau: Merck; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: ROVI; Financial Interests, Personal, Other, travel accommodation: Roche; Financial Interests, Personal, Other, travel accommodation: Novartis; Financial Interests, Personal, Other, travel accommodation: Merck. T. Puertolas Hernandez: Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Other, travel accommodation: Roche. A. Berrocal: Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Other, travel and accommodation: MSD; Financial Interests, Personal, Other, travel accommodation: BMS; Financial Interests, Personal, Other, honoraria: BMS; Financial Interests, Personal, Other, honoraria: MSD; Financial Interests, Personal, Other, honoraria: Novartis; Financial Interests, Personal, Other, honoraria: Amgen; Financial Interests, Personal, Other, honoraria: Pierre Fabre; Financial Interests, Personal, Other, honoraria: Merck; Financial Interests, Personal, Other, honoraria: Sanofi. M. Majem Tarruella: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Boehringer; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Tesaro; Financial Interests, Personal, Advisory Role: Helsinn Therapeutics; Financial Interests, Personal, Advisory Role: Takeda; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Other, travel and accommodation: AstraZeneca; Financial Interests, Personal, Other, travel accommodation: Roche; Financial Interests, Personal, Other, travel and accommodation: Lilly; Financial Interests, Personal, Research Grant: BMS. L. Bellido Hernández: Financial Interests, Personal, Other, honoraria: BMS; Financial Interests, Personal, Other, honoraria: Roche; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Boehringer. E. Espinosa: Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Other, travel accommodation: MSD; Financial Interests, Personal, Other, honoraria: BMS; Financial Interests, Personal, Other, honoraria: MSD; Financial Interests, Personal, Other, honoraria: Novartis; Financial Interests, Personal, Other, honoraria: Roche; Financial Interests, Personal, Other, honoraria: Pierre Fabre; Financial Interests, Personal, Research Grant: Roche. J. Medina Martínez: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Speaker’s Bureau: Pierre Fabre; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Other, travel accommodation: Novartis; Financial Interests, Personal, Other, travel accommodation: Roche; Financial Interests, Personal, Other, travel and accommodation: BMS; Financial Interests, Personal, Other, travel accommodation: MSD. L.A. Fernandez Morales: Financial Interests, Personal, Other, honoraria: Novartis; Financial Interests, Personal, Other, honoraria: Roche; Financial Interests, Personal, Other, honoraria: BMS; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Research Grant: Novartis; Financial Interests, Personal, Research Grant: Roche; Financial Interests, Personal, Other, travel accommodation: Pfizer; Financial Interests, Personal, Other, travel accommodation: Roche; Financial Interests, Personal, Other, travel and accommodation: Novartis. C. Aguado de la Rosa: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Other, travel accommodation: Roche. R. Lopez Castro: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Boehringer; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Other, travel accommodation: Roche; Financial Interests, Personal, Other, travel accommodation: Novartis; Financial Interests, Personal, Other, travel and accommodation: Boehringer; Financial Interests, Personal, Other, honoraria: Roche; Financial Interests, Personal, Other, honoraria: Novartis; Financial Interests, Personal, Other, honoraria: Boehringer; Financial Interests, Personal, Other, honoraria: Takeda; Financial Interests, Personal, Other, honoraria: AstraZeneca; Financial Interests, Personal, Research Grant: Roche; Financial Interests, Personal, Research Grant: MSD. S. Martin Algarra: Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Regeneron; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Speaker’s Bureau: Pierre Fabre; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Other, travel accommodation: BMS; Financial Interests, Personal, Other, travel and accommodation: Roche; Financial Interests, Personal, Other, travel accommodation: Pierre Fabre; Financial Interests, Personal, Other, travel and accommodation: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings